The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma
Published version of a preprint
Abstract
Purpose: LKB1 loss is common in lung cancer, but no assay exists to efficiently evaluate the presence or absence of LKB1. We validated an IHC assay for LKB1 loss and determined the impact of LKB1 loss in KRAS-mutant non–small cell lung cancer (NSCLC). Experimental Design: We optimized and validated an IHC assay for LKB1 (clone Ley37D/G6) using a panel of lung cancer cell lines and tumors with known LKB1 mutations, including 2 patients with Peutz–Jeghers syndrome (PJS) who developed lung adenocarcinoma. We retrospectively analyzed tumors for LKB1 using IHC from 154 KRAS-mutant NSCLC patients, including 123 smokers and 31 never-smokers, and correlated the findings with patient and tumor characteristics and clinical outcome. Results: LKB1 expression was lost by IHC in 30% of KRAS-mutant NSCLC (smokers 35% vs. never-smokers 13%, P = 0.017). LKB1 loss did not correlate with a specific KRAS mutation but was more frequent in tumors with KRAS transversion mutations (P = 0.029). KRAS-mutant NSCLC patients with concurrent LKB1 loss had a higher number of metastatic sites at the time of diagnosis (median 2.5 vs. 2, P = 0.01), higher incidence of extrathoracic metastases (P = 0.01), and developed brain metastasis more frequently (48% vs. 25%, P = 0.02). There was a nonsignificant trend to worse survival in stage IV KRAS-mutant NSCLC patients with LKB1 loss. Conclusions: LKB1 IHC is a reliable and efficient assay to evaluate for loss of LKB1 in clinical samples of NSCLC. LKB1 loss is more common in smokers, and is associated with a more aggressive clinical phenotype in KRAS-mutant NSCLC patients, accordingly to preclinical models. Clin Cancer Res; 21(12); 2851–60. ©2015 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, LKB1 loss is prevalent in KRAS mutant lung cancers46, indicating that oncogenic KRAS not only induces mTOR activity, but might also upregulate one-carbon metabolism by undermining AMPK’s inhibitory role in the folate cycle.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [46]
Citations
Cites
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Hemminki, A., Markie, D., Tomlinson, I. P. M., Avizienyte, E., Roth, S., Loukola, A., Bignell, G. R., Warren, W., Aminoff, M., Höglund, P., et al. (1998) · Nature · doi:10.1038/34432 · Cited by 1,680
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1
Lizcano, J. M., Göransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Mäkelä, T. P., Hardie, D. G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600110 · Cited by 1,381
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Peutz-Jeghers syndrome is caused by mutations in a novel serine threoninekinase
Jenne, D. E., Reomann, H., Nezu, J., Friedel, W., Loff, S., Jeschke, R., Müller, O., Back, W. E., & Zimmer, M. (1998) · Nature Genetics · doi:10.1038/ng0198-38 · Cited by 1,201
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Cited by
Sorted by citations
Items 101–115 of 115
Kim, J., Cai, F., Ko, B., Yang, C., Lee, H. M., Muhammad, N., Li, K., Haloul, M., Gu, W., Faubert, B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.13.039669 · Cited by 3
Shimada, Y., Yamamoto, T., Shindo, K., Nakanishi, Y., Matsumoto, T., Noguchi, S., Aishima, S., Nakamura, M., & Oda, Y. (2025) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002451 · Cited by 2
Leader, A. M., Neil, A., Siegmund, S., Dehghani, A., Ligon, A. H., Matulonis, U. A., Nucci, M. R., McCluggage, W. G., Howitt, B. E., & Kolin, D. L. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100891 · Cited by 2
Carrillo, J. F., Cruz-Romero, C. I., Avilés‐Salas, A., Carrillo, L. C., Ramirez-Ortega, M. C., Herrera‐Goepfert, R., Vázquez-Romo, R., Figueroa‐González, G., Altamirano-García, J. I., & Oñate-Ocaña, L. F. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11544-x · Cited by 2
Shu, C., Jin, R., Niu, Q., Cicka, D., Doyle, S. P., Wahafu, A., Fan, D., Zheng, X., Du, Y., Ivanov, A. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.17.460294 · Cited by 2
Pineda, C. M., Guan, Z., Kwon, H., Rangachari, D., Costa, D. B., & VanderLaan, P. A. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100938 · Cited by 1
Sarlak, S. (2021) · theses.fr (ABES) · doi:10.70675/2e2c5420z3a1fz49c3zb548z8e72b24a52b2 · Cited by 1
Zer, A., Tsao, M., & Shepherd, F. A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.130
Macaya, I., Entrialgo‐Cadierno, R., Valencia, K., & Vicent, S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.11.017
Cai, X., Cao, Z., Jiongwei, P. A. N., & Zheng, H. (2023) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.23.02918-8
Maso, A. D., Ferrarini, F., Esposito, G., Minuzzo, S. A., Puggia, A. M., Pezzuto, F., Zulato, E., Bao, L. C., Nuzzo, M. D., Ferro, A., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1552506
Lin, Z., Ashish, S., Huang, L., Li, S., Li, Y., Zhou, Y., & Gu, J. (2025) · Research Square · doi:10.21203/rs.3.rs-6458808/v1
Targeting cellular senescence for cancer therapy
Abduljabbar, R., Liu, Y., Mussa, A., Abdu, A. M. A., Man, Y., Chen, Q., & Liu, Z. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126297
Bandyopadhyay, S., & Gordan, J. D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.23.740219
Jin, S., Zhang, Z., Liang, F., Yang, Y., Lü, A., & Liang, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00981-5
Metadata
- Authors
- Calles, A., Sholl, L. M., Rodig, S. J., Pelton, A. K., Hornick, J. L., Butaney, M., Lydon, C., Dahlberg, S. E., Oxnard, G. R., Jackman, D. M., & Jänne, P. A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- 1Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2015-06-14
- Volume
- 21
- Issue
- 12
- Pages
- 2851-2860
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2129277646
- Cited by
- 115
- References
- 50
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 7 · 2023: 9 · 2022: 14 · 2021: 16 · 2020: 12 · 2019: 11 · 2018: 10 · 2017: 6 · 2016: 13 · 2015: 3
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- LKB1 loss, KRAS-mutant non-small cell lung cancer, lung adenocarcinoma, Peutz-Jeghers syndrome, smoking, metastasis, brain metastases, prognostic factors, tumor aggressiveness
- MeSH terms
- Adenocarcinoma of Lung, AMP-Activated Protein Kinase Kinases, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Genotype, Humans, Immunohistochemistry, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Retrospective Studies, Risk Factors, Biomarkers, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Disease Progression, Cell Line, Tumor, Kaplan-Meier Estimate, Young Adult, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
